Telomerase activity in soft-tissue and bone sarcomas

Kenjiro Aogi, Anthony Woodman, Virginia Urquidi, David C. Mangham, David Tarin, Steven Goodison

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The telomerase enzyme is a reverse transcriptase capable of replacing the telomeric DNA sequences that are lost at each cell division. Telomerase activation permits extended cell proliferation beyond normal senescence checkpoints, and accordingly, telomerase activity has been detected in a wide range of malignant cells and tissues but is absent in terminally differentiated somatic cells. To date, the majority of cancer-related telomerase analyses have been performed on carcinomas that originate from epithelial cells, and few reports have included tumors originating from nonepithelial cells. In this study, we used the PCR-based telomeric repeat amplification protocol (TRAP) to assay telomerase activity in nuclear protein extracts obtained from a range of malignant and benign connective tissue lesions. In total, 62 histologically diagnosed specimens were analyzed including 37 sarcomas, 7 benign mesenchymal tumors, 12 normal tissue samples, and 6 carcinoma metastases obtained from bone. Thirty (81%) of the 37 primary sarcoma samples contained telomerase activity, and four of the six carcinoma metastases were also positive. Conversely, telomerase activity was detectable in only one of seven benign lesions and in none of the 12 normal connective tissue controls. Tumors of connective tissue origin can sometimes be difficult to categorize and to evaluate microscopically with regard to clinical management. As is the case in carcinomas, the presence of telomerase activity appears to be indicative of malignancy in mesenchymal tumor biopsy material and therefore may be useful as an adjunct to the pathologist in the assessment of borderline cases.

Original languageEnglish (US)
Pages (from-to)4776-4781
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number12
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Telomerase
Sarcoma
Sarcoma 37
Connective Tissue
Carcinoma
Neoplasms
Neoplasm Metastasis
RNA-Directed DNA Polymerase
Nuclear Proteins
Cell Division
Epithelial Cells
Cell Proliferation
Biopsy
Bone and Bones
Polymerase Chain Reaction
Enzymes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aogi, K., Woodman, A., Urquidi, V., Mangham, D. C., Tarin, D., & Goodison, S. (2000). Telomerase activity in soft-tissue and bone sarcomas. Clinical Cancer Research, 6(12), 4776-4781.

Telomerase activity in soft-tissue and bone sarcomas. / Aogi, Kenjiro; Woodman, Anthony; Urquidi, Virginia; Mangham, David C.; Tarin, David; Goodison, Steven.

In: Clinical Cancer Research, Vol. 6, No. 12, 01.01.2000, p. 4776-4781.

Research output: Contribution to journalArticle

Aogi, K, Woodman, A, Urquidi, V, Mangham, DC, Tarin, D & Goodison, S 2000, 'Telomerase activity in soft-tissue and bone sarcomas', Clinical Cancer Research, vol. 6, no. 12, pp. 4776-4781.
Aogi K, Woodman A, Urquidi V, Mangham DC, Tarin D, Goodison S. Telomerase activity in soft-tissue and bone sarcomas. Clinical Cancer Research. 2000 Jan 1;6(12):4776-4781.
Aogi, Kenjiro ; Woodman, Anthony ; Urquidi, Virginia ; Mangham, David C. ; Tarin, David ; Goodison, Steven. / Telomerase activity in soft-tissue and bone sarcomas. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 12. pp. 4776-4781.
@article{88aa06589ee94a3698ba2895c88fffd0,
title = "Telomerase activity in soft-tissue and bone sarcomas",
abstract = "The telomerase enzyme is a reverse transcriptase capable of replacing the telomeric DNA sequences that are lost at each cell division. Telomerase activation permits extended cell proliferation beyond normal senescence checkpoints, and accordingly, telomerase activity has been detected in a wide range of malignant cells and tissues but is absent in terminally differentiated somatic cells. To date, the majority of cancer-related telomerase analyses have been performed on carcinomas that originate from epithelial cells, and few reports have included tumors originating from nonepithelial cells. In this study, we used the PCR-based telomeric repeat amplification protocol (TRAP) to assay telomerase activity in nuclear protein extracts obtained from a range of malignant and benign connective tissue lesions. In total, 62 histologically diagnosed specimens were analyzed including 37 sarcomas, 7 benign mesenchymal tumors, 12 normal tissue samples, and 6 carcinoma metastases obtained from bone. Thirty (81{\%}) of the 37 primary sarcoma samples contained telomerase activity, and four of the six carcinoma metastases were also positive. Conversely, telomerase activity was detectable in only one of seven benign lesions and in none of the 12 normal connective tissue controls. Tumors of connective tissue origin can sometimes be difficult to categorize and to evaluate microscopically with regard to clinical management. As is the case in carcinomas, the presence of telomerase activity appears to be indicative of malignancy in mesenchymal tumor biopsy material and therefore may be useful as an adjunct to the pathologist in the assessment of borderline cases.",
author = "Kenjiro Aogi and Anthony Woodman and Virginia Urquidi and Mangham, {David C.} and David Tarin and Steven Goodison",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "4776--4781",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Telomerase activity in soft-tissue and bone sarcomas

AU - Aogi, Kenjiro

AU - Woodman, Anthony

AU - Urquidi, Virginia

AU - Mangham, David C.

AU - Tarin, David

AU - Goodison, Steven

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The telomerase enzyme is a reverse transcriptase capable of replacing the telomeric DNA sequences that are lost at each cell division. Telomerase activation permits extended cell proliferation beyond normal senescence checkpoints, and accordingly, telomerase activity has been detected in a wide range of malignant cells and tissues but is absent in terminally differentiated somatic cells. To date, the majority of cancer-related telomerase analyses have been performed on carcinomas that originate from epithelial cells, and few reports have included tumors originating from nonepithelial cells. In this study, we used the PCR-based telomeric repeat amplification protocol (TRAP) to assay telomerase activity in nuclear protein extracts obtained from a range of malignant and benign connective tissue lesions. In total, 62 histologically diagnosed specimens were analyzed including 37 sarcomas, 7 benign mesenchymal tumors, 12 normal tissue samples, and 6 carcinoma metastases obtained from bone. Thirty (81%) of the 37 primary sarcoma samples contained telomerase activity, and four of the six carcinoma metastases were also positive. Conversely, telomerase activity was detectable in only one of seven benign lesions and in none of the 12 normal connective tissue controls. Tumors of connective tissue origin can sometimes be difficult to categorize and to evaluate microscopically with regard to clinical management. As is the case in carcinomas, the presence of telomerase activity appears to be indicative of malignancy in mesenchymal tumor biopsy material and therefore may be useful as an adjunct to the pathologist in the assessment of borderline cases.

AB - The telomerase enzyme is a reverse transcriptase capable of replacing the telomeric DNA sequences that are lost at each cell division. Telomerase activation permits extended cell proliferation beyond normal senescence checkpoints, and accordingly, telomerase activity has been detected in a wide range of malignant cells and tissues but is absent in terminally differentiated somatic cells. To date, the majority of cancer-related telomerase analyses have been performed on carcinomas that originate from epithelial cells, and few reports have included tumors originating from nonepithelial cells. In this study, we used the PCR-based telomeric repeat amplification protocol (TRAP) to assay telomerase activity in nuclear protein extracts obtained from a range of malignant and benign connective tissue lesions. In total, 62 histologically diagnosed specimens were analyzed including 37 sarcomas, 7 benign mesenchymal tumors, 12 normal tissue samples, and 6 carcinoma metastases obtained from bone. Thirty (81%) of the 37 primary sarcoma samples contained telomerase activity, and four of the six carcinoma metastases were also positive. Conversely, telomerase activity was detectable in only one of seven benign lesions and in none of the 12 normal connective tissue controls. Tumors of connective tissue origin can sometimes be difficult to categorize and to evaluate microscopically with regard to clinical management. As is the case in carcinomas, the presence of telomerase activity appears to be indicative of malignancy in mesenchymal tumor biopsy material and therefore may be useful as an adjunct to the pathologist in the assessment of borderline cases.

UR - http://www.scopus.com/inward/record.url?scp=0034490210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034490210&partnerID=8YFLogxK

M3 - Article

C2 - 11156234

AN - SCOPUS:0034490210

VL - 6

SP - 4776

EP - 4781

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -